Early Signs of Gastroparesis from Ozempic: Who Needs Monitoring in North Carolina?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Specific Exposure Concerns

If you take Ozempic and experience persistent nausea, bloating, or abdominal pain, these could be early signs of gastroparesis—a condition where stomach emptying slows. Understanding these symptoms and your risk factors is key to timely monitoring. Within the long tradition of medical education, this page focuses on recognizing early warning signs and knowing when to seek evaluation in North Carolina.

Ozempic and Gastrointestinal Adverse Reactions: Clinical Evidence

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Clinical trial data show that gastrointestinal adverse reactions occur significantly more frequently with Ozempic than with placebo. In placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea events occurred during dose escalation, and discontinuation due to gastrointestinal adverse reactions was higher in Ozempic groups (0.5 mg: 3.1%; 1 mg: 3.8%) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% of patients on 1 mg and 34.0% on 2 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, presenting with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. The clinical diagnosis is typically confirmed by gastric emptying scintigraphy. While Ozempic's prescribing information does not explicitly list gastroparesis as an adverse reaction, it does report less common gastrointestinal events including dyspepsia (placebo: 1.9%; 0.5 mg: 3.5%; 1 mg: 2.7%), eructation (0%; 2.7%; 1.1%), flatulence (0.8%; 0.4%; 1.5%), gastroesophageal reflux disease (0%; 1.9%; 1.5%), and gastritis (0.8%; 0.8%; 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, and the drug's mechanism—slowing gastric emptying via GLP-1 receptor agonism—provides a plausible mechanistic pathway linking Ozempic to gastroparesis. Delayed gastric emptying is a known pharmacodynamic effect of GLP-1 agonists, and prolonged use may exacerbate or unmask gastroparesis in susceptible individuals.

Legal Considerations: Statute of Limitations for Ozempic Claims in North Carolina

The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The prescribing information warns of serious hypersensitivity reactions, including anaphylaxis and angioedema, and advises caution in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no specific warning about gastroparesis as a potential adverse effect. This gap may be relevant for patients who develop gastroparesis symptoms while on Ozempic and later seek legal recourse. In North Carolina, the statute of limitations for personal injury claims, including product liability, is generally three years from the date the injury is discovered or reasonably should have been discovered. For gastroparesis allegedly caused by Ozempic, the clock may start when a patient receives a formal diagnosis or when symptoms become severe enough to prompt medical evaluation. The timeline between exposure and documented harm is critical: if a patient took Ozempic for months or years before developing gastroparesis, the discovery date may be later than the initial prescription date. Courts may consider when a reasonable person would have connected the drug to the condition, especially given the lack of explicit warnings. Settlement-related considerations for affected patients include the strength of the causal link, the severity of harm, and the adequacy of manufacturer warnings. Evidence from clinical trials shows a clear dose-response relationship for gastrointestinal adverse reactions, but gastroparesis is not specifically quantified. Patients with documented gastroparesis after Ozempic use may need to demonstrate that the drug caused or contributed to their condition, potentially relying on expert testimony about the mechanistic pathway. The absence of a gastroparesis warning could support claims of inadequate labeling. However, the statute of limitations imposes a strict deadline; patients in North Carolina should consult an attorney promptly to preserve their rights. The three-year window may be extended in cases of fraudulent concealment or continuous treatment, but these exceptions are narrow.

Summary and Next Steps for Affected Individuals

In summary, Ozempic is associated with a high rate of gastrointestinal adverse reactions, and its mechanism of slowing gastric emptying provides a plausible link to gastroparesis. The prescribing information does not specifically warn about gastroparesis, which may affect liability assessments. Patients in North Carolina alleging harm must be aware of the three-year statute of limitations from discovery of injury. Legal and medical evaluation should occur as soon as possible after diagnosis. References: (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims, including product liability, is generally three years from the date the injury is discovered or reasonably should have been discovered. For gastroparesis allegedly caused by Ozempic, the clock may start when a patient receives a formal diagnosis or when symptoms become severe enough to prompt medical evaluation. It is crucial to consult an attorney promptly to preserve your rights.

Does Ozempic's prescribing information warn about gastroparesis?

No, the prescribing information for Ozempic does not explicitly list gastroparesis as an adverse reaction. It does report less common gastrointestinal events such as dyspepsia, eructation, flatulence, gastroesophageal reflux disease, and gastritis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific gastroparesis warning may be relevant for patients seeking legal recourse.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.